Allegro Raises $4.5M to Support Commercialization of Lung Cancer Test | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Allegro Diagnostics today announced it has closed a $4.5 million Series A extension financing.

Proceeds will be used to commercialize the company's BronchoGen test in 2012. The molecular testing platform uses gene expression of normal epithelial cells in the respiratory tract for the early detection of lung cancer.

Participants in the round included existing venture investors Kodiak Venture Partners and Catalyst Health Ventures.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: genetic method to gauge age of ancient samples, genetic polymorphisms in mouse strain, and more.

Two Stanford professors are turning to the online game EteRNA to develop a new way to diagnose tuberculosis.

Lita Nelsen from the Massachusetts Institute of Technology's technology-transfer office is retiring after decades there.

After nine years, the Canadian government is loosening its restrictions on government scientists' ability to speak to the press and public.